By Assoc. Prof. Dr. Mehmet Sorar | Published: 09.02.2025
What Is TMS Therapy? How Is It Applied? Its Effect on Parkinson’s Disease
TMS therapy sends magnetic pulses through a coil placed on the head to change brain activity, without surgery or sedation. For Parkinson's disease, a European expert guideline rated certain high-frequency protocols as probably effective (Level B) for motor impairment and depression. US regulators have not cleared TMS for Parkinson's disease, and the guideline abstract does not say how large or how lasting the benefit is.
What is TMS therapy?
TMS stands for transcranial magnetic stimulation. The Cleveland Clinic describes it as a non-invasive treatment that uses magnetic pulses to change brain activity. It is neither a drug nor an operation, and it is given through a coil on the head. The word covers several forms with different session lengths, so clearance or evidence for one form does not carry over to another.
In the United States the first clearance for a TMS device came in 2008, for depression, according to the 2022 timeline by Cohen and colleagues. Later clearances cover obsessive-compulsive disorder, migraine with aura, short-term help with quitting smoking and depression with anxiety. Parkinson's disease is not among them. The page on what TMS is sets out the forms and the clearance list in full.
How is a TMS session applied?
The Cleveland Clinic describes the same steps for any condition, so nothing here is specific to Parkinson's disease. Metal items are removed and you sit in a reclining chair. Because the machine clicks loudly, you wear earplugs or headphones. The coil is placed on your head, test pulses set the strength, and treatment pulses follow. You may feel tapping on the scalp or a twitch in the thumb or hand.
Depending on the type of TMS, a session lasts about 3 to 40 minutes. Standard repetitive TMS usually takes 20 to 40 minutes and theta-burst about 3 to 10. The Cleveland Clinic gives a typical schedule of 5 days a week for 4 to 6 weeks, often about 30 to 36 sessions for depression, and says some people need maintenance sessions later. No session number or programme for Parkinson's disease appears in this guidance, so ask what any proposed schedule is based on. The 2021 expert guideline from the International Federation of Clinical Neurophysiology (IFCN) sets minimum training requirements for the people who operate the equipment.
For Parkinson's disease, the guideline by Lefaucheur and colleagues names high-frequency stimulation of the motor cortex on both sides, or of the left prefrontal cortex, as the protocols that reached Level B. The motor cortex is the brain region that directs movement.
What does the evidence say about its effect on Parkinson's disease?
The evidence is at the level of probable efficacy, which is not the same as proven. The 2020 guideline by Lefaucheur and colleagues searched the literature to the end of 2018 and gave Level B to Parkinson's disease for motor impairment or depression. Level A, meaning definite efficacy, was reached only for neuropathic pain, depression and hand recovery after stroke.
A level reflects how consistently real stimulation beat sham (fake) stimulation in enough independent studies. The abstract gives no effect size, the authors caution that a statistically supported benefit may not matter clinically, and nothing in it concerns the course of the disease. The guideline is more than five years old and does not include later work. The page on Parkinson's disease and TMS goes through symptoms one by one and compares TMS with deep brain stimulation.
Is TMS cleared for Parkinson's disease?
No. The Cleveland Clinic lists Parkinson's disease among the conditions under study but not cleared by the US Food and Drug Administration (FDA), and it does not appear in the FDA timeline of cleared uses. No separate clearance is listed for depression that occurs with Parkinson's disease.
The manufacturer BrainsWay says the European CE mark of its device covers a broader list that includes Parkinson's disease. That is the company's own statement, and its page does not say which clinical evidence supports it. It should not be read as proof of benefit. For the related Parkinson Plus conditions, evidence is more limited again, and the page on TMS in Parkinson Plus conditions covers them.
What rules TMS out, and what side effects are reported?
Several implants and conditions rule TMS out. In people with Parkinson's disease the most relevant is a deep brain stimulator, which both the Cleveland Clinic (implanted brain stimulators) and the Oxford Health NHS Foundation Trust leaflet (2026) list as a reason not to give TMS. Both sources also give these:
- Metal or electronic implants in the head or neck that cannot be removed, such as cochlear implants, aneurysm clips or coils, metal plates and shrapnel.
- A pacemaker or defibrillator. The Oxford leaflet says the manufacturer advises against use with a cardiac pacemaker.
- Epilepsy. The Oxford service does not usually treat people with epilepsy, and the Cleveland Clinic says a seizure history or medicines that lower the seizure threshold raise the risk.
The usual side effects are headache, scalp discomfort and mild facial twitching. Seizure is the most serious and is very rare. The Oxford leaflet puts the risk at less than 1 in 30,000 to 50,000 per treatment, possibly higher with its accelerated protocol, and other sources give other figures. Those are compared on the page about TMS safety data.
Which questions help before you decide on TMS therapy?
The most useful questions are about the target symptom and the evidence behind the protocol:
- Is the aim to improve movement or to treat depression?
- Which region and which frequency will be used, and is that the protocol the guideline rated Level B?
- Do I have a deep brain stimulator or another implant, and does that change suitability?
- Which studies support the expected benefit, and how large and how lasting was it?
- How will progress be measured, and when will the programme be stopped if it is not helping?
Which changes need emergency help or a report before the next session?
Get emergency help for a seizure or loss of consciousness away from the clinic. Report a headache that keeps getting worse or a new implant before the next session. The full list:
- Any seizure during or after a session, even if it stopped by itself.
- A headache that simple painkillers do not relieve or that increases. The Oxford leaflet says headache usually settles with simple painkillers and eases as sessions go on.
- A new implant, or a new or changed medicine. Alcohol use or lack of sleep before sessions can raise the seizure risk, according to the Oxford leaflet.
- Worsening mood or thoughts of harming yourself. Seek medical help at once.
Keep taking your Parkinson's medicines as prescribed, and leave any change to the doctor who prescribes them. The sessions themselves are described on the page about what a TMS session involves.
Sources
- Cleveland Clinic: Transcranial Magnetic Stimulation (TMS)
- Lefaucheur et al.: Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018), Clinical Neurophysiology 2020
- Cohen et al.: A visual and narrative timeline of US FDA milestones for Transcranial Magnetic Stimulation (TMS) devices, Brain Stimulation 2022
- BrainsWay (device manufacturer, commercial source): What Mental Health Conditions Is Deep TMS FDA-Cleared To Treat?
- Oxford Health NHS Foundation Trust: rTMS patient information leaflet (v7.0, 2026)
- Rossi et al.: Safety and recommendations for TMS use in healthy subjects and patient populations (IFCN expert guidelines), Clinical Neurophysiology 2021
This article is for general information and does not replace medical diagnosis or treatment. Please consult your physician for advice about your own condition.
Assoc. Prof. Dr. Mehmet Sorar
Neurosurgeon in Ankara. Graduated from Gazi University Faculty of Medicine in 1997, specialist since 2004, associate professor since 2019. Full CV
Related treatment page: TMS Tedavisi